Impact de l'inflammation sur le STP et la personnalisation des traitements
Débuté dans le cadre notre workshop pré-congrès de la SFPT à Lyon en 2019, nous avons le plaisir de vous communiquer la suite de ce travail sous la forme d'un article de revue publié dans Pharmacology & Therapeutics en juillet 2020.
par Françoise Stanke-Labesqueab1; Elodie Gautier-Veyretab1 ; Stephanie Chhuncde1; Romain Guilhaumoufg1; on behalf of the French Society of Pharmacology and Therapeutics.
Abstract
Inflammation is an evolutionary process that allows survival against acute infection or injury. Inflammation is also a pathophysiological condition shared by numerous chronic diseases. In addition, inflammation modulates important drug-metabolizing enzymes and transporters (DMETs), thus contributing to intra- and interindividual variability of drug exposure. A better knowledge of the impact of inflammation on drug metabolism and its related clinical consequences would help to personalize drug treatment.
Here, we summarize the kinetics of inflammatory mediators and the underlying transcriptional and post-transcriptional mechanisms by which they contribute to the inhibition of important DMETs. We also present an updated overview of the effect of inflammation on the pharmacokinetic parameters of most of the drugs that are DMET substrates, for which therapeutic drug monitoring is recommended. Furthermore, we provide opinions on how to integrate the inflammatory status into pharmacogenetics, therapeutic drug monitoring, and population pharmacokinetic strategies to improve the personalization of drug treatment for each patient.